DA 9801

Drug Profile

DA 9801

Alternative Names: DA9801

Latest Information Update: 09 Oct 2015

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Phytotherapies
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetic neuropathies

Highest Development Phases

  • Phase II Diabetic neuropathies

Most Recent Events

  • 09 Oct 2015 Phase-II clinical trials in Diabetic neuropathies in South Korea (PO)
  • 01 Oct 2013 Phase-II clinical trials in Diabetic neuropathies in USA (PO) (NCT01822925)
  • 31 Aug 2013 Dong-A ST completes a phase II trial in Diabetic neuropathies in South Korea (NCT01813799)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top